MAZE logo

MAZEMaze Therapeutics Inc.

$24.27
$1.13
(4.45%)
Today
Closed $24.27
$0.00
(0.00%)
After Hours
Updated: 04:30 PM EDT
Reported EarningsMay 12
Mkt Cap$1.34B
Vol445,615.00
44

Bearish Sentiment

How do you feel about MAZE?

News
all
press releases
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?
Key PointsCEO Jason Coloma sold 32,564 shares in May for a total transaction value of approximately $847,000, at a weighted average price around $26.01 per share...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares...
Yahoo! Finance: News
News Placeholder
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
Maze Therapeutics, Inc. (MAZE) delivered earnings and revenue surprises of -5.07% and +23.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Rating of "Buy" by Analysts
Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been given a consensus rating of "Buy" by the eleven brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and two ha...
MarketBeat
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $190,275.00 in Stock
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $25.37, for a total transaction of $190,275.00. Following the sale, the insider directly...
MarketBeat
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up - Here's Why
Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up - Should You Buy...
MarketBeat
News Placeholder
Maze Therapeutics Prices $150 Mln Stock, Pre-Funded Warrants Offering
(RTTNews) - Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company, on Wednesday, announced the pricing of an underwritten registered offering of stock and pre-funded warrants expected to raise approximately $150 million in gross proceeds...
Nasdaq News: Markets
News Placeholder
239,994 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Mass General Brigham Inc
Mass General Brigham Inc acquired a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen cut shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Sees Unusually-High Trading Volume - Here's What Happened
Maze Therapeutics (NASDAQ:MAZE) Sees Unusually-High Trading Volume - Here's Why...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.